Investor Relations

Latest Financial Results

Feb 22, 2024 4:05 PM EST

FY 2023 Year End Results

Fiscal Year Ended Dec 31, 2023

Latest news

TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada

View press release

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

View press release

Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024

View press release

Latest presentation

Maravai Corporate Presentation

Latest event

Q4 2023 Maravai LifeSciences Earnings Conference Call

Investor R&D Day 2023

Latest financial results

Latest annual filing

For fiscal year ending Dec 31, 2023

Company overview

Maravai LifeSciences is a leading life sciences company providing critical products to enable the development of novel vaccines, drug therapies, and diagnostics, and to support research on human diseases. Our customers include top global biopharmaceutical companies and many other emerging biopharmaceutical and life sciences research companies, as well as leading academic research institutions and in vitro diagnostics companies. Our products address the key phases of biopharmaceutical development spanning research to commercialization and include complex nucleic acids for vaccine, therapeutic and diagnostic applications, custom enzymes for research and diagnostic use and antibody-based products to detect impurities during the production of biopharmaceutical products. We provide products that support our customers from discovery through commercialization of their vaccines, therapeutic agents and in vitro diagnostic products.  Our products are offered under the following brands:

  • TriLink BioTechnologies is a global leader in RNA synthesis and scale up, including mRNA production, yield-enhancing proprietary CleanCap® mRNA capping technology, and CDMO services ranging from research to GMP grades.
  • Glen Research leads in specialty reagents for DNA and RNA oligonucleotide synthesis for a broad range of applications.
  • Cygnus Technologies developed the market for bioprocess impurity detection, process-related impurity analytics and viral clearance prior to human trials, regulatory approval and commercial release.
  • Alphazyme is a manufacturer of molecular biology enzymes, featuring a growing portfolio of enzymes used in the fields of molecular diagnostics and nucleic acid therapies.

Maravai holds a number of patents and offers innovative products and services including CleanCap®, CleanAmp®, GMPLink™, Antibody Affinity Extraction™ (AAE™), EndonucleaseGTP®, PROTEIN A MIX-N-GO™, MockV®, Sterling™, Glen Pak™, Glen Gel-Pak™, and Poly-Pak™.

Maravai's portfolio companies are ISO-9001:2015 certified and have earned hundreds of thousands of citations in peer-reviewed scientific publications.

Stock Snapshot

IR contacts


Maravai LifeSciences Holdings, Inc.
10770 Wateridge Circle
Suite 200
San Diego, CA 92121
United States

Transfer agent

Equiniti Trust Company, LLC (“EQ”)
48 Wall Street, Floor 23
New York, NY 10005
United States